Ikena Oncology is again shrinking its herd and signaling a tough fight ahead as one of two assets, a TEAD1-selective Hippo pathway inhibitor, is cut. The cancer biotech is laying off more than half of ...

ROCHESTER, N.Y. — One of Rochester’s largest employers, Paychex, is cutting its local workforce. The payroll company confirms what it calls a “reprioritization” of the company. A spokesperson for the ...

One of Rochester’s largest employers, Paychex, Inc., laid off some employees last week. In an emailed statement, the company confirmed the move, writing: “We are continuously reprioritizing roles ...

On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...

I rate Rocket Pharmaceuticals a hold, given its strategic shift to late-stage AAV cardiovascular therapies and disciplined capital allocation. The company is cutting costs, reducing staff by 30%, and ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic ...

Cellectar Biosciences (CLRB) announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic ...

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on ...

The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of Allocetra TM as an innovative, ...

– Pipeline reprioritization emphasizes NASH and COVID-19 assets, ALG-055009 and ALG-097558, plus key ongoing collaborations, including the Merck & Co. (MSD) programs in NASH – – Overall workforce ...